The spectrum of primary drug resistance of Mycobacterium tuberculosis in patients with tuberculosis in relation to human immunodeficiency virus status
- Authors: Zimina VN1, Mikova OE2, Varetskaya TA2, Oborin DA2, Degtyareva SY.1, Sergevnin VI3
-
Affiliations:
- ФГАОУ ВО «Российский университет дружбы народов»
- ГКУЗ Пермского края «Пермский краевой центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»
- ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е.А. Вагнера» Минздрава России
- Issue: Vol 89, No 11 (2017)
- Pages: 50-54
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32311
- DOI: https://doi.org/10.17116/terarkh2017891150-54
- ID: 32311
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V N Zimina
ФГАОУ ВО «Российский университет дружбы народов»Москва, Россия
O E Mikova
ГКУЗ Пермского края «Пермский краевой центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»Пермь, Россия
T A Varetskaya
ГКУЗ Пермского края «Пермский краевой центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»Пермь, Россия
D A Oborin
ГКУЗ Пермского края «Пермский краевой центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»Пермь, Россия
S Yu Degtyareva
ФГАОУ ВО «Российский университет дружбы народов»Москва, Россия
V I Sergevnin
ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е.А. Вагнера» Минздрава РоссииПермь, Россия
References
- WHO End TB strategy. WHO. Published 2015. Available at: http://www.who.int/tb/post2015_strategy/en/ Accessed May 31,2017
- World Health Organization. Global Tuberculosis Report 2016.; 2016. https://doi.org/ISBN 978 92 4 156539 4. Accessed May 31, 2017. Available at: http://www.who.int/tb/publications/global_report/en/
- Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med. 2017;5(3):191-199. https://doi.org/10.1016/S2213-2600(16)30423-4
- Aung KJM, Van Deun A, Declercq E, et al. Successful «9-month Bangladesh regimen» for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-1187. https://doi.org/10.5588/ijtld.14.0100
- Moodley R, Godec TR. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29-35. https://doi.org/10.1183/16000617.0080-2015
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switz. 2016. Accessed 31 May, 2017. Available at: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/
- Campos PE, Suarez PG, Sanchez J, et al. Tuberculosis in HIV-Infected. Emerg Infect Dis. 2003;9(12):1571-1578. https://doi.org/10.3201/eid0912.020731
- Churchyard G.J., Corbett E.L., Kleinschmidt I., Mulder D., De Cock K.M. Drug-resistant tuberculosis in South African gold miners: Incidence and associated factors. Int J Tuberc Lung Dis. 2000;4(5):433-440.
- Mac-Arthur AJ, Gloyd S, Perdigao P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int J Tuberc Lung Dis. 2001;5(10):894-902.
- Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: Analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5(10):887-893.
- Quy HT, Buu TN, Cobelens FGJ, Lan NTN, Lambregts CSB, Borgdorff MW. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 2006;10(2):160-166.
- Mesfin YM, Hailemariam D, Biadglign S, Kibret KT, Glaziou P. Association between HIV/AIDS and Multi-Drug Resistance Tuberculosis: A Systematic Review and Meta-Analysis. Shukla D, ed. PLoS One. 2014;9(1):e82235. https://doi.org/10.1371/journal.pone.0082235
- Sahai J, Gallicano K, Swick L, al et. Reduced plasma concentrations of antituberculosis drugs in patients with HIV-infection. Ann Intern Med. 1997;127(4):289-293. https://doi.org/10.7326/0003-4819-127-4-199708150-00006
- Gurumurthy P, Ramachandran G, Kumar AKH, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human ummunodeficiency virus disease. Society. 2004;48(11):4473-4475. https://doi.org/10.1128/AAC.48.11.4473
- Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993;53(3):292-297.
- Van Oosterhout JJ, Dzinjalamala FK, Dimba A, et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother. 2015;59(10):6175-6180. https://doi.org/10.1128/AAC.01193-15
- Корецкая Н.М., Большакова И.А. Биологические свойства микобактерий у ВИЧ-негативных и ВИЧ-позитивных лиц с диссеминированным туберкулезом легких. Сибирское медицинское обозрение. 2012;4:62-66.
- WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response.; 2010. Accessed May 31, 2017. Available at: http://www.who.int/tb/features_archive/m_xdrtb_facts/en/
- Conaty SJ, Hayward AC, Story A, Glynn JR, Drobinewski FA, Watson JM. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol Infect. 2004;132(6):1099-1108. https://doi.org/10.1017/S0950268804002869
- ЦНИИ ОИЗ. Эпидемическая ситуация по туберкулезу в России. Ссылка активна на 31.05.2017. Доступно по: http://mednet.ru/ru/czentr-monitoringa-tuberkuleza.html
- Пантелеев А.М. Патогенез, клиника, диагностика и лечение туберкулеза у больных ВИЧ-инфекцией: диссертация на соискание степени доктора медицинских наук. Санкт-Петербург, 2012. Ссылка активна на 31.05.2017. http://www.dissercat.com/content/patogenez-klinika-diagnostika-i-lechenie-tuberkuleza-u-bolnykh-vich-infektsiei
- Khanin A, Viktorova I, Kononchuk O. Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia. Eur Respir J. 2016;48(suppl.60). Accessed May 31, 2017. Available at: http://erj.ersjournals.com/content/48/suppl_60/PA2765
- Покровский В.В., Ладная Н.Н., Буравцова Е.В. Сирица А.В. ВИЧ-инфекция: информ. бюл. №41. 2016:55.
- Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156-168. https://doi.org/10.1183/09031936.00134712
- Ahmad S, Mokaddas E, Al-Mutairi N, Eldeen HS, Mohammadi S. Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country. PLoS One. 2016;11(4):1-16. https://doi.org/10.1371/journal.pone.0153563
- Banu S, Rahman SMM, Khan MSR, et al. Discordance across several methods for drug susceptibility testing of drug-resistant mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol. 2014;52(1):156-163. https://doi.org/10.1128/JCM.02378-13
- Yakrus MA, Driscoll J, Lentz AJ, et al. Concordance between molecular and phenotypic testing of mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol. 2014;52(6):1932-1937. https://doi.org/10.1128/JCM.00417-14
- Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol. 2009;47(11):3501-3506. https://doi.org/10.1128/JCM.01209-09